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Abstract
Background: Neurocysticercosis (NCC) is an invasive parasitic infection of the 
central nervous system caused by the larval stage of the tapeworm Taenia solium. 
The clinical manifestations of NCC depend on the parasitic load and location of 
infection, as well as the developmental stage of the cysticerci and host immune 
response, with symptoms ranging from subclinical headaches to seizures, 
cerebrovascular events, and life‑threatening hydrocephalus. Racemose NCC 
represents a particularly severe variant of extraparenchymal NCC characterized 
by the presence of multiple confluent cysts within the subarachnoid space and is 
associated with increased morbidity and mortality, as well as a decreased response 
to treatment. Albendazole is the preferred drug for the treatment of racemose NCC 
due to its superior cerebrospinal fluid penetration compared to praziquantel and 
the ability to be used concomitantly with steroids.
Case Description: In this report, we describe a 39‑year‑old man recently 
emigrated from Mexico with racemose NCC and hydrocephalus successfully 
treated with prolonged albendazole treatment, high‑dose dexamethasone, and 
ventriculoperitoneal shunt placement for the relief of obstructive hydrocephalus.
Conclusions: Treatment of racemose NCC represents a significant clinical 
challenge requiring multimodal intervention to minimize infectious‑ and 
treatment‑related morbidity. We review the clinical, diagnostic, and therapeutic 
features relevant to the management of this aggressive form of NCC.
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INTRODUCTION
Neurocysticercosis (NCC) is a common parasitic 
infection of the central nervous system (CNS) caused 
by the tapeworm Taenia solium. Infection is typically 
characterized by the presence of intraparenchymal 
cysts within the cerebral hemispheres at the gray‑white 
junction and NCC is the most frequent cause of 
acquired epilepsy in the developing countries.[17] Parasitic 
infestation is endemic to South and Central America, 
Southeast Asia, China, and Sub‑Saharan Africa[6] and 
is of increasing importance in the United States due 
to high volumes of immigration from these endemic 
areas.[6,14,24] Extraparenchymal NCC is less common 
than the intraparenchymal form and is defined as 
NCC involving the subarachnoid, meningeal, and 
intraventricular space. Extraparenchymal NCC presents 
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unique diagnostic and therapeutic challenges compared 
to the intraparenchymal form. The racemose variant of 
extraparenchymal NCC represents a particularly aggressive 
infection and is associated with relatively increased 
morbidity and mortality and decreased responsiveness to 
medical treatment. The variant is characterized by the 
presence of multilobulated confluent cysts within the 
basal subarachnoid space that appear “grape‑like” both 
radiographically and pathologically.[6] In this report, we 
describe the successful management of a patient with 
extensive racemose NCC and hydrocephalus treated 
with cerebrospinal fluid (CSF) diversion and prolonged 
administration of albendazole and corticosteroids with 
complete radiographic and clinical resolution of infection.
CASE REPORT
A 39‑year‑old male presented to the emergency 
room with a complaint of worsening headaches and 
visual decline. The patient emigrated from Mexico 
13 months prior to presentation and reported no 
other significant medical history. He described diffuse 
headaches that had progressed over a 1‑month period 
with new‑onset bilateral visual impairment and nausea 
for the last week. His neurologic exam was nonfocal, 
however, the ophthalmologic evaluation revealed 
bilateral papilledema and diminished visual acuity. He 
was afebrile on presentation and without meningeal 
irritation signs. Initial laboratory findings indicated a 
normal white blood cell count of 7400/mm3 with 73% 
polymorphonuclear leukocytes, 21% lymphocytes, and 
1% eosinophils. A head computed tomography (CT) 
scan demonstrated hydrocephalus with transependymal 
flow and a multilobulated hypodense mass in the basal 
cisterns. Subsequent magnetic resonance imaging (MRI) 
was performed which demonstrated the presence of too 
numerous to count nonenhancing, T2‑hyperintense 
cystic lesions in the lateral ventricles and subarachnoid 
spaces including the bilateral sylvian fissures and 
cerebellopontine angles, as well as the suprasellar, 
interpeduncular, and prepontine cisterns with the largest 
cyst measuring 21 mm in diameter and exerting mild 
mass effect upon the brainstem [Figure 1]. Minor sylvian 
fissure enhancement was noted bilaterally, however, 
magnetic resonance angiography (MRA) showed no large 
vessel stenosis or occlusion. A screening MRI of the spine 
demonstrated a small subarachnoid cystic lesion at the 
level of the conus and multiple septations at the S1–S2 
level. A lumbar puncture was performed, and an elevated 
opening pressure was documented. CSF analysis revealed 
a mild lymphocytic pleocytosis with 60 white blood 
cells/mm3 (96% lymphocytes, 4% eosinophils). The initial 
CSF protein level was 106 mg/dL with a glucose level 
of 54 mg/dL. CSF cysticercus antibody ELISA testing 
was positive, and a diagnosis of racemose NCC was 
made based on the immunoassay results, neuroimaging 
findings, and a history of recent emigration from Mexico.
After extensive discussion between the neurosurgical and 
infectious diseases teams, we elected to proceed with 
placement of a ventriculoperitoneal shunt to ameliorate 
his elevated intracranial pressure and communicating 
hydrocephalus. High‑dose dexamethasone (4 mg QID) 
was initiated followed by administration of prolonged 
albendazole (10 mg/kg/day) treatment. The patient 
experienced immediate relief of his visual deficit 
following the CSF diversion treatment. He maintained 
a mild headache disorder that responded well to 
steroids, and he was able to be slowly weaned off of this 
medication over a 12 month period. MRI scan performed 
at that time revealed complete radiographic resolution 
of his subarachnoid, spinal, and intraventricular cystic 
lesions with very mild persistent meningeal enhancement 
[Figure 2]. A serum cysticercus antigen ELISA test was 
nonreactive, and albendazole was discontinued.
DISCUSSION
Cysticercosis is the most common helminthic infection 
of the CNS with infection occurring primarily through 
the ingestion of eggs of the parasitic tapeworm 
T. solium.[13] The eggs hatch within the digestive system 
and the released oncospheres penetrate the intestinal 
mucosa to enter the circulation. The oncospheres are then 
passively transported to various tissues including the brain, 
Figure 1: (a) Axial T2-weighted magnetic resonance imaging 
demonstrating multiple confluent cystic lesions in the basal 
cisterns and sylvian fissures. (b) Fluid-attenuated inversion recovery 
magnetic resonance imaging showing multiple cystic lesions with the 
largest cyst measuring 21 mm in maximal diameter (dashed arrow) 
and mild mass effect on the brainstem. (c) Sagittal T1-weighted 
magnetic resonance imaging postgadolinium administration 
showing hydrocephalus and cystic lesions in suprasellar, prepontine, 
and foramen magnum cisterns. (d) Fluid-attenuated inversion 
recovery magnetic resonance imaging demonstrating multiple 
cystic lesions within the lateral ventricles bilaterally (arrows) with 
enlarged ventricles and transependymal flow
ba
c d
Surgical Neurology International 2016, 7:12 http://www.surgicalneurologyint.com/content/7/1/12
muscle, and eyes where the parasites form larval cysts, or 
cysticerci. Extraparenchymal NCC occurs as the cysticerci 
reach the ventricles through the choroid plexus where they 
may pass freely or become attached to the ependyma.[16] 
Intraventricular infection appears to be more frequent than 
previously believed with recent series documenting the 
presence of parasitic cysts in up to 30% of patients with 
NCC.[9] Displacement of the cysts from the ventricles via 
the CSF may lead to infection within the basal cisterns, 
sylvian fissures, and cortical and spinal subarachnoid 
spaces. Excessive basal subarachnoid infection involving 
numerous parasitic membranes and enlarged vesicular 
cysts accompanied by a relative lack of scolices is termed 
racemose NCC, although no definitive diagnostic criteria 
for this rare but severe variant have been described.[6]
The diagnosis of racemose NCC is typically based on 
neuroimaging, serum and CSF laboratory evaluation, 
and clinical, epidemiologic data including immigration 
from or frequent travel to disease‑endemic areas. 
Contrast‑enhanced MRI is the imaging modality of 
choice for the detection of extraparenchymal NCC 
as CT has limited sensitivity for identification of 
intraventricular and small subarachnoid cysts.[16] Lesions 
typically appear as hyperintense on T2‑weighted 
sequences and provide a clear delineation of the cyst 
wall and the presence of obstructive or communicating 
hydrocephalus. Contrast evaluation is important to 
determine the extent of the host inflammatory response 
including ependymitis and basal arachnoiditis, as well as 
the evolutionary stage of the parasite. While the clinical 
and neuroimaging findings are of paramount importance, 
serologic testing may provide additional data, especially 
in patients without an appropriate epidemiologic history. 
Peripheral eosinophilia is a common but nonspecific 
finding with NCC.[8] Similarly, the presence of CSF 
eosinophils is frequently indicative of NCC and is a 
helpful in differentiating NCC from other forms of 
infectious chronic meningitis, although this finding has 
been reported to occur in only 15% of patients.[9] The 
most common CSF abnormalities observed with NCC 
are a mild‑moderate lymphocytic pleocytosis and increase 
in protein with the levels varying according to parasitic 
burden and location of the infection. Positive serum 
and CSF immunoassays for detection of anticysticercal 
antibodies are highly suggestive of NCC infection in 
the appropriate clinical setting, although false‑negative 
results are a well‑recognized limitation.[8] The sensitivity 
of these immunoassays has not been established for the 
racemose variant but would be expected to be increased 
given the robust inflammatory reaction typically elicited 
with subarachnoid infection.
The intraventricular and cisternal forms of NCC typically 
manifest in a more clinically aggressive manner than 
parenchymal infection and frequently cause intracranial 
hypertension due to CSF outflow obstruction or 
inflammatory basal arachnoiditis.[21] Cysts within the 
ventricular cavities may be free floating and cause 
obstruction at the foramina of Monro, sylvian aqueduct, 
or fourth ventricle and may present with rapid clinical 
deterioration secondary to acute hydrocephalus. These 
cysts may also become attached to the ependymal wall 
of the ventricle and result in ependymitis following cyst 
degeneration that may lead to intraventricular loculation 
and make CSF diversion more problematic. Similarly, cyst 
degeneration within the subarachnoid space may elicit 
an accompanying host inflammatory response with basal 
arachnoiditis, vasculitis, elevated intracranial pressure, 
and subacute to chronic hydrocephalus requiring CSF 
diversion. In 2002, DeGiorgio et al. demonstrated that 
patients with heavy cyst burdens and hydrocephalus 
carried the highest risk of mortality with NCC, 
primarily because of elevated intracranial pressure and 
shunt‑related problems.[7] Similarly, Colli et al. reported 
a 30.8% mortality in patients who required placement 
of a ventriculoperitoneal shunt and a >80% rate of 
shunt failure secondary to shunt obstruction due to 
proteinaceous debris.[4] In addition to hydrocephalus, 
the active inflammatory process may lead to vasculitis 
and cerebrovascular complications. Angiography or MRA 
may reveal segmental narrowing or occlusion of large 
vessels within the basal cisterns and sylvian fissures, with 
the majority of infarcts occurring in the lenticulostriate 
artery distributions.[3] Basal meningitis may also cause 
cranial nerve dysfunction due to fibrous entrapment.[16] 
Callacondo et al. recently described that extension of 
infection to the spinal subarachnoid space is very common 
in racemose NCC, with spinal involvement documented 
in 17 of 28 patients in their prospective study leading the 
authors to recommend that screening MRI of the spine 
be performed in basal subarachnoid disease to document 
spinal involvement, prevent complications, and monitor 
for recurrent infection.[2]
Figure 2: (a) Axial T2-weighted magnetic resonance imaging 
showing cyst resolution within the basal cisterns and sylvian 
fissures. (b) Fluid-attenuated inversion recovery magnetic resonance 
imaging showing resolution of the multiple cystic lesions within the 
lateral ventricles and hydrocephalus
ba
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No consensus exists regarding the optimal treatment of 
racemose NCC including the duration of anthelmintic 
treatment and the role of surgical intervention. In 
patients presenting with hydrocephalus, the priority 
is relief of raised intracranial pressure.[14] Obstructive 
hydrocephalus due to intraventricular cysts is best 
managed endoscopically via cyst removal or drainage 
and often obviates the need for permanent shunt 
placement.[8,19] Intraventricular cysts may be freely mobile 
and imaging immediately prior to neuroendoscopic 
intervention is recommended to confirm the location 
of the cyst. A relative contraindication for endoscopic 
removal of intraventricular cysts is the presence of 
significant ependymal enhancement as this typically 
indicates dense adhesion between the parasitic cyst 
and the ependymal wall with attempted cyst removal 
associated with neurologic injury and intraventricular 
hemorrhage.[10,20] A role for endoscopic or microsurgical 
removal of subarachnoid cysts within the basal cisterns 
and sylvian fissures is less established due to frequently 
high cyst burden and widespread subarachnoid 
distribution and inflammatory response. Giant 
(>5 cm) subarachnoid cysts with associated mass effect 
and intracranial hypertension are most often managed 
surgically, although Proaño et al. demonstrated complete 
resolution of giant cysts in 19 of 33 patients treated 
medically with prolonged multicourse anthelmintic and 
corticosteroid therapy.[18] Couldwell et al. suggested that 
surgical therapy be reserved for cisternal forms of NCC if 
initial medical management fails or experiences neurologic 
decline as conventional microsurgical approaches have 
been associated with significant morbidity, likely due 
to the presence of arachnoiditis with adherence of the 
cyst walls to cranial nerves and arteries.[5] More recently, 
several authors have described minimally invasive 
keyhole or endoscopic approaches to the basal cisterns 
to achieve cyst drainage, although the utility of these 
approaches for extensive subarachnoid disease has yet 
to be established.[1] Fortunately, spillage of cyst contents 
with these approaches has not proven to exacerbate 
the inflammatory response in the postoperative period, 
although careful attention to this concern and copious 
intraoperative irrigation are recommended.[11,12]
In our patient with hydrocephalus and relatively rapid 
progression of visual loss, given the bilateral sylvian 
fissure involvement and absence of any dominant cystic 
lesion or focal neurologic deficits, we elected to proceed 
with placement of a ventriculoperitoneal shunt prior to 
initiating therapy directed against the invasive infection. 
Delayed exacerbation of intracranial hypertension 
frequently occurs several days following administration 
of cysticidal agents as a result of cyst degeneration and 
subsequent host inflammatory response with the release 
of proinflammatory cytokines.[6,23] For this reason, steroids 
should be administered concurrently with anthelmintic 
therapy to reduce the inflammatory response. 
Subarachnoid cysts are considered less responsive to 
pharmacologic therapy compared to intraparenchymal 
lesions, with albendazole the preferred drug for 
treatment of racemose NCC due to its superior CSF 
penetration compared to praziquantel.[8] Additionally, 
the CNS distribution of albendazole is less affected 
by steroid administration.[22] The dose and duration of 
treatment must be individually tailored to each patient 
depending on their parasitic burden and clinical and 
radiographic response to treatment with the treatment 
course frequently longer than that prescribed for the 
parenchymal disease. Aggressive medical treatment 
has been shown to decrease the incidence of shunt 
malfunction, which has been directly linked to poorer 
clinical outcome.[15] For patients with giant cysts, 
Proaño et al. achieved excellent results with a 4 weeks 
course of albendazole, although more than half of their 
patients required more than one treatment course to 
achieve cyst resolution. 4 of the 33 patients in their study 
required 3 or more months of therapy and 10 patients 
also received praziquantel following a failure of the cysts 
to respond to albendazole.[18]
CONCLUSION
In our patient, we reported the successful clinical 
resolution of racemose NCC following CSF diversion 
and prolonged anthelmintic therapy and corticosteroid 
administration to prevent the development of chronic 
subarachnoid inflammation. No shunt complications or 
revisions occurred, and a complete radiographic response 
was observed. Racemose NCC represents a, fortunately, 
rare but aggressive form of extraparenchymal NCC 
often resulting in basilar arachnoiditis, vasculitis, and 
cranial neuropathy. Proper recognition of this infection 
and appropriate management with careful consideration 
of the deleterious effects of the attendant host 
inflammatory response to cyst degeneration is necessary 
to reduce patient morbidity and mortality. Racemose 
NCC accompanied by intracranial hypertension and 
hydrocephalus is associated with poorer clinical outcomes, 
often related to ventriculoperitoneal shunt infection 
and malfunction. Vigilant clinical and radiographic 
monitoring of response to treatment is imperative to 
reduce neurologic sequelae and infection relapse as 
prolonged, or multicourse medical therapy is frequently 
necessary.
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